Don’t count on selenium to prevent lung cancer, suggests studyJune 6th, 2010 - 1:38 pm ICT by ANI
Washington, June 6 (ANI): A new study has shown that taking the popular mineral supplement selenium doesn’t reduce the likelihood of lung cancer recurrence.
Lead author Daniel D. Karp, a professor in the department of thoracic/head and neck medical oncology at the University of Texas M.D. Anderson Cancer Center, presented the finding at the American Society of Clinical Oncology annual meeting, in Chicago.
“Several epidemiological and animal studies have long-suggested a link between deficiency of selenium and cancer development,” said Karp.
“Interest and research escalated in the late 1990s after a skin cancer and selenium study, published in 1996, found no benefit against the skin cancer, but did suggest an approximate 30 percent reduction of prostate and lung cancers. Our lung cancer research and another major study for the prevention of prostate cancer evolved from that finding,” he added.
But the new study found that among more than 1,500 stage 1 (early) non-small cell lung cancer patients who had survived their initial bout with the disease, selenium offered no protection against recurrence or the onset of a new cancer or second primary cancer.
The patients were tracked from 2000 to 2009, after all had undergone surgery to remove their initial tumors and remained cancer-free for a minimum of six months post-treatment.
Half the patients were placed on a regimen of 200 micrograms of selenium, while the other half took a placebo.
Those in the placebo group had better survival rates five years later than those taking the supplement — an observation that led the research team to halt the study earlier than planned.
While 78 percent taking the placebo stayed alive over that time frame, the rate was just 72 percent among the selenium group. And while 1.4 percent of the placebo group developed a second primary tumor within a year, that figure rose to 1.9 percent among the selenium group, the researchers said.
Some benefit of selenium was observed in a small group of patients who had never smoked, but the study authors said the group was too small to render the finding meaningful. (ANI)
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- Vitamin E supplement ups chances of prostate cancer - Oct 12, 2011
- Gene set shows which patients benefit from chemo after surgery - Sep 08, 2010
- Key component in the spread of lung cancer discovered - Mar 15, 2011
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- Trace elements in toenails show up cancer risk - Dec 20, 2011
- Synthetic compound may lead to drugs to fight pancreatic, lung cancer - Mar 10, 2011
- Shark cartilage does not improve lung cancer survival - May 27, 2010
- Diets high in fish oil 'help maintain weight during chemotherapy' - Feb 28, 2011
- TTF therapy, chemo combo 'increase survival for lung cancer patients' - Oct 11, 2010
- Targeted drug therapy shows promise against deadly form of lung cancer - Nov 02, 2010
- Soy 'ups radiation's ability to destroy lung cancer cells' - Apr 02, 2011
- New discovery shows promise against non-small cell lung cancer - Dec 04, 2010
- Melanoma-initiating cell identified - Jul 01, 2010
- Fish oil fights weight loss from chemotherapy - Feb 28, 2011
Tags: anderson cancer center, benef, cancer development, cancer recurrence, cell lung cancer, initial bout, lung cancer patients, lung cancer research, lung cancers, m d anderson cancer center, medical oncology, non small cell lung cancer, placebo group, prevention of prostate cancer, prostate cancer, selenium group, skin cancer, small cell lung cancer, survival rates, university of texas m d anderson cancer center